Dupilumab
| Evidence Level: L3 | Predicted Indications: 9 |
Table of Contents
Dupilumab: Bronchitis
One-Sentence Summary
Dupilumab is a monoclonal antibody originally used to treat atopic eczema (atopic dermatitis). The TxGNN model predicts it may be effective for bronchitis, but the evidence is indirect: 1 clinical trial (in a related upper-airway disease) and 11 publications (mostly on asthma and COPD) are currently linked to this prediction. Note that the strongest-scoring evidence in the data compiled for this report points to other conditions (see the notes in the conclusion).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 0.9992 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 4 of 4) |
| Number of DINs | 4 (marketed: 4) |
| Recommended Decision | Hold (treat as a research question) |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available in the structured drug record. However, the literature compiled for this report consistently describes dupilumab as an antibody that binds the IL-4 receptor alpha subunit (IL-4Rα), blocking signalling of both IL-4 and IL-13, two key drivers of type 2 inflammation.
Atopic dermatitis is a type 2 inflammatory disease, and dupilumab’s efficacy there is well established. Some forms of airway disease share this inflammatory pathway. Strong evidence exists for dupilumab in asthma (a long-term extension study and a meta-analysis of randomized trials) and in type 2 (eosinophilic) COPD, where real-world cohorts, including patients with a chronic bronchitis phenotype, report benefit.
The label “bronchitis” is broad, though. Evidence for bronchitis itself is limited to a case-level report on eosinophilic plastic bronchitis. The prediction is probably best interpreted as type 2 COPD or eosinophilic bronchial disease, and it should be narrowed to one of these before any decision.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04362501 | Phase 2 | Completed | 33 | Randomized, placebo-controlled study of dupilumab in chronic rhinosinusitis without nasal polyps. This is an upper-airway type 2 disease, not bronchitis, so relevance is indirect. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34597534 | 2022 | RCT extension | Lancet Respir Med | TRAVERSE: long-term safety and efficacy of dupilumab in moderate-to-severe asthma |
| 30273510 | 2019 | Meta-analysis | J Asthma | Systematic review of RCTs of dupilumab versus placebo in uncontrolled asthma |
| 39904363 | 2025 | Systematic review | Tuberc Respir Dis | Comprehensive review of drug therapies for preventing COPD exacerbations |
| 42617837 | 2026 | Comparative study | Chest | Mepolizumab and dupilumab showed no significant difference in reducing exacerbations in eosinophilic COPD (indirect comparison) |
| 42839285 | 2026 | Real-world cohort | Respir Res | German multicentre real-world effectiveness of dupilumab in COPD |
| 42511891 | 2026 | Case series | Biomedicines | 12 patients with type 2 COPD (chronic bronchitis phenotype) treated with dupilumab under compassionate use |
| 42773542 | 2026 | Review | Eur J Clin Invest | Updates in COPD management, including targeted therapies |
| 38488768 | 2024 | Review | Pediatr Pulmonol | Novel therapies for eosinophilic pediatric plastic bronchitis |
| 41672525 | 2026 | Case report | Intern Med | Two cases of eosinophilic bronchiolitis successfully treated with biologics, including dupilumab |
| 32428511 | 2020 | Clinical study | Chest | Effect of anti-type 2 biologics on lung ventilation (MRI) in prednisone-dependent asthma |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02510049 | DUPIXENT | Not specified | Not specified |
| 02524252 | DUPIXENT | Not specified | Not specified |
| 02492504 | DUPIXENT | Not specified | Not specified |
| 02470365 | DUPIXENT | Not specified | Not specified |
Safety Considerations
Drug Interactions: 53 interactions were identified. Examples include:
- Major: adalimumab, baricitinib, certolizumab pegol, cladribine
- Moderate: warfarin, roflumilast, azathioprine, cyclosporine, anakinra, denosumab, dimethyl fumarate, a live cholera vaccine
- Minor: zinc salts (acetate, gluconate, sulfate, chloride)
Other safety signals appear in the literature compiled for this report, such as head and neck dermatitis, conjunctivitis, and psoriasiform reactions occurring during dupilumab therapy. Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for bronchitis is supported by strong evidence in related diseases (asthma and type 2 COPD), but direct evidence for bronchitis is limited to case-level reports, and the only listed trial concerns chronic rhinosinusitis. The best use of this finding is as a research question to be refined.
Other predictions from this analysis:
- Exanthem (rank 4, L3): Early support in cutaneous immune-related adverse events, but the literature also contains reports of dupilumab-induced rashes, so caution is warranted.
- Acne keloid (rank 3, L4): Only one case-level publication; Hold.
- Ranks 5-10: Little or no evidence and weak mechanistic rationale (e.g. dermatomyositis, diabetic retinopathy); these are likely network artifacts. Hold.
To proceed, the following is needed:
- Narrow the indication (e.g. eosinophilic or type 2 COPD with chronic bronchitis) and review the existing COPD trial data
- Package insert warnings and contraindications from Health Canada
- Mechanism-of-action data in the drug record
- Approved indication text and dosage forms for the Canadian licences
- A plan to evaluate interaction risks with other biologics and immunosuppressants
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.